ROTTERDAM, Netherlands and SAN DIEGO, Jan. 9, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company focused on the research and development of molecular diagnostics, is excited to announce that the European Patent Office (EPO) has granted European Patent No. 3827101, marking a groundbreaking advancement in the field of cancer diagnostics and personalized treatment.
Regulatory
Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma
Bristol Myers Squibb’s (BMS) Opdualag (nivolumab-relatlimab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line treatment of advanced melanoma in patients aged 12 years and older.
NICE Approves Nivolumab and Relatlimab Combination for Advanced Melanoma Treatment
The National Institute for Health and Care Excellence (NICE) has made a significant stride in the management of advanced melanoma by approving the drug combination of nivolumab and relatlimab as a first-line treatment.
FDA Approves First AI-Powered Skin Cancer Diagnostic Tool
DermaSensor provides quantitative, point-of-testing identification for skin cancer, including melanoma, basal cell carcinoma, and squamous cell carcinoma.